Wall Street Zen Upgrades HUTCHMED (NASDAQ:HCM) to Strong-Buy

Wall Street Zen upgraded shares of HUTCHMED (NASDAQ:HCM - Free Report) from a buy rating to a strong-buy rating in a report issued on Friday morning.

Separately, HSBC cut HUTCHMED from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th.

HUTCHMED Stock Performance

Shares of HCM traded down $0.05 during mid-day trading on Friday, reaching $15.05. 36,393 shares of the stock traded hands, compared to its average volume of 100,388. The company has a quick ratio of 2.70, a current ratio of 2.83 and a debt-to-equity ratio of 0.08. HUTCHMED has a 1 year low of $11.51 and a 1 year high of $21.50. The firm has a fifty day moving average price of $14.79 and a 200 day moving average price of $14.63.

Institutional Trading of HUTCHMED

Several hedge funds have recently added to or reduced their stakes in the business. Barclays PLC raised its stake in shares of HUTCHMED by 1,483.6% during the fourth quarter. Barclays PLC now owns 2,407 shares of the company's stock valued at $35,000 after acquiring an additional 2,255 shares during the last quarter. Public Employees Retirement System of Ohio raised its stake in HUTCHMED by 49.6% in the fourth quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company's stock worth $39,000 after buying an additional 899 shares in the last quarter. Summit Trail Advisors LLC grew its holdings in HUTCHMED by 7.7% in the first quarter. Summit Trail Advisors LLC now owns 14,094 shares of the company's stock worth $212,000 after purchasing an additional 1,004 shares during the period. OLD Mission Capital LLC purchased a new stake in HUTCHMED in the fourth quarter worth about $230,000. Finally, Marshall Wace LLP purchased a new stake in HUTCHMED in the fourth quarter worth about $261,000. 8.82% of the stock is owned by institutional investors.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.